Christopher W Ryan

Summary

Affiliation: Oregon Health and Science University
Country: USA

Publications

  1. doi request reprint A phase II study of tasisulam sodium (LY573636 sodium) as second-line or third-line treatment for patients with unresectable or metastatic soft tissue sarcoma
    Christopher W Ryan
    Section of Hematology Oncology, Oregon Health and Science University Knight Cancer Institute, Portland, OR, USA
    Invest New Drugs 31:145-51. 2013
  2. ncbi request reprint A phase I/II dose-escalation study of exisulind and docetaxel in patients with hormone-refractory prostate cancer
    Christopher W Ryan
    Division of Hematology and Medical Oncology, Oregon Health and Science University, Portland, OR 97239 3098, USA
    BJU Int 95:963-8. 2005
  3. ncbi request reprint Zoledronic acid initiated during the first year of androgen deprivation therapy increases bone mineral density in patients with prostate cancer
    Christopher W Ryan
    Division of Hematology Oncology, Oregon Health and Science University, 3181 Southwest Sam Jackson Park Road, Portland, OR 97239, USA
    J Urol 176:972-8; discussion 978. 2006
  4. ncbi request reprint A phase II trial of O6-benzylguanine and carmustine in patients with advanced soft tissue sarcoma
    Christopher W Ryan
    Division of Hematology and Medical Oncology, Oregon Health and Science University, 3181 SW Sam Jackson Park Rd CR145, Portland, OR 97239, USA
    Cancer Chemother Pharmacol 58:634-9. 2006
  5. ncbi request reprint Lifestyle factors and duration of androgen deprivation affect bone mineral density of patients with prostate cancer during first year of therapy
    Christopher W Ryan
    Cancer Institute, Oregon Health and Science University, Portland, Oregon 97239, USA
    Urology 70:122-6. 2007
  6. ncbi request reprint Suppression of bone density loss and bone turnover in patients with hormone-sensitive prostate cancer and receiving zoledronic acid
    Christopher W Ryan
    Division of Hematology and Medical Oncology, Oregon Health and Science University, 3303 SW Bond Avenue, Portland, OR 97239, USA
    BJU Int 100:70-5. 2007
  7. doi request reprint Histologic response of dose-intense chemotherapy with preoperative hypofractionated radiotherapy for patients with high-risk soft tissue sarcomas
    Christopher W Ryan
    Department of Medicine, Division of Hematology and Medical Oncology, Oregon Health and Science University, Portland, OR 97239, USA
    Cancer 112:2432-9. 2008
  8. ncbi request reprint Dose-ranging study of the safety and pharmacokinetics of atrasentan in patients with refractory malignancies
    Christopher W Ryan
    Section of Hematology Oncology, Department of Medicine, Cancer Research Center, and Committee on Clinical Pharmacology and Pharmacogenomics, University of Chicago, Chicago, and Abbott Laboratories, Abbott Park, Illinois, USA
    Clin Cancer Res 10:4406-11. 2004
  9. doi request reprint A phase II study of everolimus in combination with imatinib for previously treated advanced renal carcinoma
    Christopher W Ryan
    Oregon Health and Science University Knight Cancer Institute, Portland, OR 97239, USA
    Invest New Drugs 29:374-9. 2011
  10. doi request reprint C-reactive protein as a prognostic marker for men with androgen-independent prostate cancer: results from the ASCENT trial
    Tomasz M Beer
    Division of Hematology and Medical Oncology, Oregon Health and Sciences University, Portland, OR 97239, USA
    Cancer 112:2377-83. 2008

Detail Information

Publications44

  1. doi request reprint A phase II study of tasisulam sodium (LY573636 sodium) as second-line or third-line treatment for patients with unresectable or metastatic soft tissue sarcoma
    Christopher W Ryan
    Section of Hematology Oncology, Oregon Health and Science University Knight Cancer Institute, Portland, OR, USA
    Invest New Drugs 31:145-51. 2013
    ..Secondary objectives included objective response rate (ORR), clinical benefit rate (CBR), overall survival (OS), pharmacokinetics, and safety...
  2. ncbi request reprint A phase I/II dose-escalation study of exisulind and docetaxel in patients with hormone-refractory prostate cancer
    Christopher W Ryan
    Division of Hematology and Medical Oncology, Oregon Health and Science University, Portland, OR 97239 3098, USA
    BJU Int 95:963-8. 2005
    ....
  3. ncbi request reprint Zoledronic acid initiated during the first year of androgen deprivation therapy increases bone mineral density in patients with prostate cancer
    Christopher W Ryan
    Division of Hematology Oncology, Oregon Health and Science University, 3181 Southwest Sam Jackson Park Road, Portland, OR 97239, USA
    J Urol 176:972-8; discussion 978. 2006
    ..We evaluated the effect of zoledronic acid initiated subsequent to androgen deprivation therapy on bone mineral density and biochemical markers of bone turnover...
  4. ncbi request reprint A phase II trial of O6-benzylguanine and carmustine in patients with advanced soft tissue sarcoma
    Christopher W Ryan
    Division of Hematology and Medical Oncology, Oregon Health and Science University, 3181 SW Sam Jackson Park Rd CR145, Portland, OR 97239, USA
    Cancer Chemother Pharmacol 58:634-9. 2006
    ..We performed a phase II study to explore the activity of O6-BG in combination with BCNU in patients with advanced soft tissue sarcoma...
  5. ncbi request reprint Lifestyle factors and duration of androgen deprivation affect bone mineral density of patients with prostate cancer during first year of therapy
    Christopher W Ryan
    Cancer Institute, Oregon Health and Science University, Portland, Oregon 97239, USA
    Urology 70:122-6. 2007
    ..We sought to examine the impact of ADT and lifestyle variables on BMD in 120 patients with prostate cancer without bone metastases entering a randomized clinical trial...
  6. ncbi request reprint Suppression of bone density loss and bone turnover in patients with hormone-sensitive prostate cancer and receiving zoledronic acid
    Christopher W Ryan
    Division of Hematology and Medical Oncology, Oregon Health and Science University, 3303 SW Bond Avenue, Portland, OR 97239, USA
    BJU Int 100:70-5. 2007
    ....
  7. doi request reprint Histologic response of dose-intense chemotherapy with preoperative hypofractionated radiotherapy for patients with high-risk soft tissue sarcomas
    Christopher W Ryan
    Department of Medicine, Division of Hematology and Medical Oncology, Oregon Health and Science University, Portland, OR 97239, USA
    Cancer 112:2432-9. 2008
    ..The authors studied a dose-intense regimen of epirubicin and ifosfamide with hypofractionated preoperative radiotherapy for high-risk soft tissue sarcomas. The primary objective was estimation of the rate of >or=95% pathologic necrosis...
  8. ncbi request reprint Dose-ranging study of the safety and pharmacokinetics of atrasentan in patients with refractory malignancies
    Christopher W Ryan
    Section of Hematology Oncology, Department of Medicine, Cancer Research Center, and Committee on Clinical Pharmacology and Pharmacogenomics, University of Chicago, Chicago, and Abbott Laboratories, Abbott Park, Illinois, USA
    Clin Cancer Res 10:4406-11. 2004
    ..This Phase I study sought to determine the toxicity and pharmacokinetics of daily atrasentan in a population of both female and male subjects with advanced malignancies...
  9. doi request reprint A phase II study of everolimus in combination with imatinib for previously treated advanced renal carcinoma
    Christopher W Ryan
    Oregon Health and Science University Knight Cancer Institute, Portland, OR 97239, USA
    Invest New Drugs 29:374-9. 2011
    ..The primary endpoint was estimation of the 3-month progression-free rate...
  10. doi request reprint C-reactive protein as a prognostic marker for men with androgen-independent prostate cancer: results from the ASCENT trial
    Tomasz M Beer
    Division of Hematology and Medical Oncology, Oregon Health and Sciences University, Portland, OR 97239, USA
    Cancer 112:2377-83. 2008
    ..The authors sought to determine whether specific blood proteins associated with inflammation predict for outcomes in men with metastatic androgen-independent prostate cancer (AIPC) who are initiating docetaxel-based chemotherapy...
  11. doi request reprint A phase II study of high-dose calcitriol combined with mitoxantrone and prednisone for androgen-independent prostate cancer
    Joseph S Chan
    Oregon Health and Science University, Portland, OR 97239, USA
    BJU Int 102:1601-6. 2008
    ..To evaluate the preliminary efficacy, safety, and impact on quality of life (QoL) of high-dose calcitriol (DN-101) combined with mitoxantrone and glucocorticoids in androgen-independent prostate cancer (AIPC)...
  12. ncbi request reprint Intermittent chemotherapy in patients with metastatic androgen-independent prostate cancer: results from ASCENT, a double-blinded, randomized comparison of high-dose calcitriol plus docetaxel with placebo plus docetaxel
    Tomasz M Beer
    Division of Hematology and Medical Oncology, Oregon Health and Science University, Portland, Oregon 97239, USA
    Cancer 112:326-30. 2008
    ..In the current study, the authors examined retreatment with the same regimen after a treatment holiday...
  13. ncbi request reprint Double-blinded randomized study of high-dose calcitriol plus docetaxel compared with placebo plus docetaxel in androgen-independent prostate cancer: a report from the ASCENT Investigators
    Tomasz M Beer
    Division of Hematology and Medical Oncology, Department of Medicine, Oregon Health and Science University, Portland, OR 97239, USA
    J Clin Oncol 25:669-74. 2007
    ..To compare the safety and activity of DN-101, a new high-dose oral formulation of calcitriol designed for cancer therapy, and docetaxel with placebo and docetaxel...
  14. ncbi request reprint High dose pulse calcitriol, docetaxel and estramustine for androgen independent prostate cancer: a phase I/II study
    Natasha M Tiffany
    Division of Hematology and Medical Oncology, Oregon Health Sciences University and Portland Veterans Affairs Medical Center, Portland 97239, USA
    J Urol 174:888-92. 2005
    ....
  15. ncbi request reprint Diethylstilbestrol and docetaxel: a Phase II study of tubulin active agents in patients with metastatic, androgen-independent prostate cancer
    R Bruce Montgomery
    Department of Medicine, Veterans Affairs Puget Sound Health Care System VAPSHCS, and University of Washington School of Medicine, Seattle, WA 98108, USA
    Cancer 110:996-1002. 2007
    ..The addition of diethylstilbestrol to docetaxel modified tubulin composition and improved the response of prostate cancer to chemotherapy in preclinical models. An attempt was made to recapitulate the observations in a clinical trial...
  16. pmc Correlation of kinase genotype and clinical outcome in the North American Intergroup Phase III Trial of imatinib mesylate for treatment of advanced gastrointestinal stromal tumor: CALGB 150105 Study by Cancer and Leukemia Group B and Southwest Oncology Gr
    Michael C Heinrich
    Division of Hematology Oncology, Department of Medicine and Cell and Developmental Biology, Portland Veterans Affairs Medical Center and Oregon Health and Science University Cancer Institute, Portland, OR 97239, USA
    J Clin Oncol 26:5360-7. 2008
    ..In previous studies, GIST genotype correlated with treatment outcome and optimal imatinib dosing...
  17. doi request reprint A phase II study of paclitaxel poliglumex in combination with transdermal estradiol for the treatment of metastatic castration-resistant prostate cancer after docetaxel chemotherapy
    Tomasz M Beer
    Knight Cancer Institute, Oregon Health and Science University, 3303 SW Bond Ave, Portland, OR 97239, USA
    Anticancer Drugs 21:433-8. 2010
    ..The median time to progression was 4 weeks. In conclusion, this regimen of low-dose transdermal estradiol induction followed by PPX does not have activity in taxane pretreated patients with castration-resistant prostate cancer...
  18. ncbi request reprint Prognostic factors for survival with gemcitabine plus 5-fluorouracil based regimens for metastatic renal cancer
    Walter M Stadler
    University of Chicago, Illinois 60637, USA
    J Urol 170:1141-5. 2003
    ..To identify patient subgroups most likely to benefit and compare survival to that in previously described patient series long-term survival as a function of known and suspected prognostic variables was determined...
  19. ncbi request reprint Southwest Oncology Group phase II study of irinotecan in patients with advanced transitional cell carcinoma of the urothelium that progressed after platinum-based chemotherapy
    Tomasz M Beer
    Oregon Health and Science University Cancer Institute, Portland, OR 97239, USA
    Clin Genitourin Cancer 6:36-9. 2008
    ..The purpose of this study was to characterize the activity and toxicity of irinotecan in metastatic platinum-refractory urothelial carcinoma...
  20. doi request reprint Southwest Oncology Group phase II study of ispinesib in androgen-independent prostate cancer previously treated with taxanes
    Tomasz M Beer
    Oregon Health and Science University Cancer Institute, Portland, OR 97239, USA
    Clin Genitourin Cancer 6:103-9. 2008
    ..In this study, we sought to assess the efficacy of ispinesib, a mitotic kinesin spindle protein (KSP) inhibitor in androgen-independent prostate cancer progressing after docetaxel...
  21. ncbi request reprint Testosterone loss and estradiol administration modify memory in men
    Tomasz M Beer
    Department of Medicine, Division of Hematology and Medical Oncology, Oregon Health and Science University, Portland, Oregon, USA
    J Urol 175:130-5. 2006
    ..We characterized the impact of androgen deprivation and of subsequent estradiol therapy on the long-term and working memory of patients with prostate cancer...
  22. ncbi request reprint Effects of transdermal estrogen on levels of lipids, lipase activity, and inflammatory markers in men with prostate cancer
    Jonathan Q Purnell
    Department of Medicine, Division of Endocrinology, Diabetes, and Clinical Nutrition, Oregon Health and Science University, Portland, OR 97239, USA
    J Lipid Res 47:349-55. 2006
    ..Compared with ADT, short-term TDE therapy of prostate cancer improves lipid levels without deterioration of CVD-associated inflammatory markers and may, on longer-term follow-up, improve CVD and mortality rates...
  23. ncbi request reprint Phase II trial of PS-341 in patients with renal cell cancer: a University of Chicago phase II consortium study
    Nancy B Davis
    Section of Hematology Oncology, University of Chicago Medical Center, 5841 S Maryland Avenue, MC 2115, Chicago, IL 60637, USA
    J Clin Oncol 22:115-9. 2004
    ..Determine response rate, time to disease progression, and toxicity of the proteasome inhibitor PS-341 in patients with stage IV renal cell cancer...
  24. doi request reprint Phase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the kit receptor tyrosine kinase: S0033
    Charles D Blanke
    Oregon Health and Science University Cancer Institute, 3181 SW Sam Jackson Park Rd, L 586, Portland, OR 97239, USA
    J Clin Oncol 26:626-32. 2008
    ....
  25. ncbi request reprint Sorafenib with interferon alfa-2b as first-line treatment of advanced renal carcinoma: a phase II study of the Southwest Oncology Group
    Christopher W Ryan
    Oregon Health and Science University, Portland, OR, USA
    J Clin Oncol 25:3296-301. 2007
    ..This phase II study evaluated the activity of combined treatment with interferon alfa-2b and sorafenib, a Raf and multiple receptor tyrosine kinase inhibitor, in patients with advanced renal carcinoma...
  26. ncbi request reprint High dose calcitriol may reduce thrombosis in cancer patients
    Tomasz M Beer
    Division of Hematology and Medical Oncology, Oregon Health and Science University, Portland, OR 97239, USA
    Br J Haematol 135:392-4. 2006
    ..In vitro and vitamin D receptor (VDR) knockout mouse studies predict that nanomolar concentrations of calcitriol may act as an antithrombotic agent. We report the first clinical observation that supports this hypothesis in humans...
  27. ncbi request reprint A phase II trial of intravenous gemcitabine and 5-fluorouracil with subcutaneous interleukin-2 and interferon-alpha in patients with metastatic renal cell carcinoma
    Christopher W Ryan
    Department of Medicine, Section of Hematology Oncology, University of Chicago, Chicago, Illinois, USA
    Cancer 94:2602-9. 2002
    ....
  28. doi request reprint Safety and efficacy results of the advanced renal cell carcinoma sorafenib expanded access program in North America
    Walter M Stadler
    Department of Medicine, University of Chicago Medical Center, Chicago, Illinois
    Cancer 116:1272-80. 2010
    ..The Advanced Renal Cell Carcinoma Sorafenib (ARCCS) program made sorafenib available to patients with advanced renal cell carcinoma (RCC) before regulatory approval...
  29. ncbi request reprint Surgical treatment of gastrointestinal stromal tumors in the imatinib (STI-571) era
    Peter C Wu
    Department of Surgery, University of Chicago, 5841 S Maryland Avenue, Chicago, IL 60637, USA
    Surgery 134:656-65; discussion 665-6. 2003
    ..Imatinib mesylate is a selective inhibitor of tyrosine kinase-mediated activity. This study reports a single-institution experience of surgical resection and the use of imatinib in the treatment of GIST...
  30. pmc Phase I study of ixabepilone, mitoxantrone, and prednisone in patients with metastatic castration-resistant prostate cancer previously treated with docetaxel-based therapy: a study of the department of defense prostate cancer clinical trials consortium
    Jonathan E Rosenberg
    Department of Medicine, University of California San Franscisco, Helen Diller Family Comprehensive Cancer Center, 1600 Divisadero St, Box 1711, San Francisco, CA 94115, USA
    J Clin Oncol 27:2772-8. 2009
    ..Mitoxantrone plus prednisone and ixabepilone each have modest activity as second-line chemotherapy in docetaxel-refractory castration-resistant prostate cancer (CRPC) patients. Clinical noncrossresistance was previously observed...
  31. ncbi request reprint Phase I study of weekly DN-101, a new formulation of calcitriol, in patients with cancer
    Tomasz M Beer
    Division of Hematology and Medical Oncology, Department of Medicine, Oregon Health and Science University, Mail Code CR 145, 3181 SW Sam Jackson Park Road, Portland, OR 97239, USA
    Cancer Chemother Pharmacol 59:581-7. 2007
    ..DN-101 is a new, high-dose, oral formulation of calcitriol under investigation for the treatment of cancer. We sought to evaluate the tolerability and pharmacokinetics (PK) of weekly doses of DN-101 in patients with advanced cancer...
  32. ncbi request reprint A randomized Phase II trial of the antiangiogenic agent SU5416 in hormone-refractory prostate cancer
    Walter M Stadler
    University of Chicago Phase II Consortium, University of Chicago, Section of Hematology Oncology, Chicago, Illinois 60637, USA
    Clin Cancer Res 10:3365-70. 2004
    ..In vitro assessment of SU5416 on PSA secretion was assessed in the LNCaP cell line. Baseline serum basic fibroblast growth factor and plasma vascular endothelial growth factor (VEGF) were explored as prognostic factors...
  33. ncbi request reprint A phase I study of suramin with once- or twice-monthly dosing in patients with advanced cancer
    Christopher W Ryan
    Department of Medicine, Section of Hematology Oncology, University of Chicago MC2115, 5841S Maryland Ave, Chicago, IL 60637, USA
    Cancer Chemother Pharmacol 50:1-5. 2002
    ..The purpose of this study was to determine the maximum tolerated dose and toxicities of suramin when administered using a fixed dosing scheme on a once- or twice-monthly schedule...
  34. ncbi request reprint A phase II trial of UFT and leucovorin in women 65 years and older with advanced breast cancer
    Supriya Gupta
    Department of Medicine, The University of Chicago, Chicago, Illinois, USA
    Am J Clin Oncol 28:65-9. 2005
    ..Although UFT/leucovorin had efficacy in 1 patient, toxicity in the patients over 70 years of age was increased. Careful evaluation of anticancer drug toxicity in very elderly patients is important as our population ages...
  35. ncbi request reprint Phase II study of transdermal estradiol in androgen-independent prostate carcinoma
    Lisa B Bland
    Division of Urology, Oregon Health and Science University and Portland Veterans Affairs Medical Center, Portland, Oregon, 97239, USA
    Cancer 103:717-23. 2005
    ..The authors tested the safety and efficacy of transdermal estradiol (TDE), as well as the effect of therapy on hot flashes, sex hormones, the procoagulant cascade, and bone turnover in patients with AIPC...
  36. ncbi request reprint Current clinical trials in renal cell carcinoma
    Mitchell H Sokoloff
    Department of Surgery, Section of Urologic Oncology, Division of Urology and Renal Transplantation, Portland, OR 97239 3098, USA
    Urol Oncol 23:289-92. 2005
    ..This review highlights several key trials currently available for patients with kidney cancer...
  37. pmc MDM2 Amplification and PI3KCA Mutation in a Case of Sclerosing Rhabdomyosarcoma
    Ken Kikuchi
    Pediatric Cancer Biology Program, Department of Pediatrics, Papé Family Pediatric Research Institute, Oregon Health and Science University, 3181 S W Sam Jackson Park Road, Mail Code L321, Portland, OR 97239 3098, USA
    Sarcoma 2013:520858. 2013
    ..Nevertheless, MDM2 and PIK3CA are genes worthy of further investigation in patients with sclerosing rhabdomyosarcoma and might be considered in the enrollment of these patients into clinical trials of targeted therapeutics...
  38. pmc Overcoming autopsy barriers in pediatric cancer research
    Jennifer L Alabran
    Pediatric Cancer Biology Program, Papé Family Pediatric Research Institute, Oregon Health and Science University, Portland, OR 97239 3098, USA
    Pediatr Blood Cancer 60:204-9. 2013
    ..The purpose of this study was to identify barriers to autopsies and develop guidelines for requesting autopsies for research purposes...
  39. ncbi request reprint Patients presenting with CNS lesions. Case 2. Subdural presentation of recurrent breast cancer
    J Lee Villano
    Department of Medicine, University of Chicago, IL, USA
    J Clin Oncol 21:4060-2. 2003
  40. ncbi request reprint Managing bone loss in men with locally advanced prostate cancer receiving androgen deprivation therapy
    Ron S Israeli
    Staten Island Urological Research, Staten Island, New York, USA
    J Urol 179:414-23. 2008
    ..We reviewed the pathogenesis, diagnosis, prevalence, prevention and treatment of bone loss in patients with nonmetastatic prostate cancer receiving androgen deprivation therapy...
  41. ncbi request reprint A phase 2 study of carboplatin plus docetaxel in men with metastatic hormone-refractory prostate cancer who are refractory to docetaxel
    Robert W Ross
    Lank Center for Genitourinary Oncology, Dana Farber Cancer Institute, Boston, Massachusetts 02115, USA
    Cancer 112:521-6. 2008
    ..The authors conducted a phase 2 trial of docetaxel plus carboplatin chemotherapy in this disease setting...
  42. ncbi request reprint A phase II study of nilutamide in men with prostate cancer after the failure of flutamide or bicalutamide therapy
    Nancy B Davis
    Division of Neoplastic Diseases and Related Disorders, Medical College of Wisconsin, Milwaukee, WI, USA
    BJU Int 96:787-90. 2005
    ..To determine the prostate-specific antigen (PSA) response and time to PSA or radiographic progression in men with prostate cancer refractory to bicalutamide and/or flutamide therapy...
  43. ncbi request reprint Adjuvant weekly docetaxel for patients with high risk prostate cancer after radical prostatectomy: a multi-institutional pilot study
    Adam S Kibel
    Siteman Cancer Center, Washington University School of Medicine, St Louis, Missouri 63105, USA
    J Urol 177:1777-81. 2007
    ..Patients with adverse pathological features are at high risk for recurrence following radical prostatectomy. To improve outcomes in this population we performed a phase II study of adjuvant docetaxel in these high risk patients...
  44. ncbi request reprint The hazards of intermediate endpoints
    Tomasz M Beer
    Cancer 110:1877-9. 2007